Amplia Therapeutics Limited (ASX:ATX)

Amplia Therapeutics Income Statement

Financials in millions AUD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Other Revenue	3.78	4.45	1.19	1.98	1.53
Revenue	3.78	4.45	1.19	1.98	1.53
Revenue Growth (YoY)	-15.02%	274.34%	-40.02%	29.33%	4380.44%
Cost of Revenue	0.21	0.44	0.31	0.15	0.31
Gross Profit	3.57	4.01	0.88	1.83	1.22
Selling, General & Admin	2.67	2.6	2.2	1.64	1.13
Research & Development	7.53	5.8	4.69	3.77	2.21
Operating Expenses	10.37	8.58	7.17	5.47	3.56
Operating Income	-6.79	-4.57	-6.29	-3.64	-2.34
Interest Expense	-0.06	-0.08	-0.05	-0	-
Interest & Investment Income	0.28	0.15	0.1	0	0
EBT Excluding Unusual Items	-6.57	-4.5	-6.24	-3.64	-2.34
Other Unusual Items	-	-	-	-	0.06
Pretax Income	-6.57	-4.5	-6.24	-3.64	-2.28
Net Income	-6.57	-4.5	-6.24	-3.64	-2.28
Net Income to Common	-6.57	-4.5	-6.24	-3.64	-2.28
Shares Outstanding (Basic)	307	194	194	146	95
Shares Outstanding (Diluted)	307	194	194	146	95
Shares Change (YoY)	58.35%	0.02%	33.27%	53.71%	95.36%
EPS (Basic)	-0.02	-0.02	-0.03	-0.03	-0.02
EPS (Diluted)	-0.02	-0.02	-0.03	-0.03	-0.02
Free Cash Flow	-6.89	-5.13	-5.31	-4.42	-2.92
Free Cash Flow Per Share	-0.02	-0.03	-0.03	-0.03	-0.03
Gross Margin	94.44%	90.07%	74.14%	92.20%	79.65%
Operating Margin	-179.51%	-102.64%	-528.45%	-183.72%	-152.60%
Profit Margin	-173.69%	-101.14%	-524.80%	-183.74%	-148.75%
Free Cash Flow Margin	-182.04%	-115.20%	-446.19%	-222.68%	-190.52%
EBITDA	-6.78	-4.56	-6.28	-3.64	-2.34
EBITDA Margin	-179.24%	-102.40%	-	-183.56%	-152.56%
D&A For EBITDA	0.01	0.01	0.01	0	0
EBIT	-6.79	-4.57	-6.29	-3.64	-2.34
EBIT Margin	-179.51%	-102.64%	-	-183.72%	-152.60%
Revenue as Reported	4.06	4.6	1.29	1.98	1.59

Updated Nov 27, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.